LOGIN
ID
PW
MemberShip
2025-07-08 22:13
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Latecomer psoriasis drug Bimzelx enters competition in KOR
by
Whang, byung-woo
Jun 13, 2025 06:03am
The new psoriasis treatment Bimzelx (bimekizumab) has cleared the reimbursement hurdle and is now officially entering Korea¡¯s market competition. With numerous psoriasis treatment options already on the market, the drug is expected to target new patients based on its relatively low drug price. On the 12th, UCB Korea held a press conferenc
Company
New ADC drug Padcev seeks reimb again in Korea
by
Eo, Yun-Ho
Jun 13, 2025 06:03am
The ADC bladder cancer drug Padcev is once again attempting reimbursement listing in Korea. According to Dailypharm coverage, Astellas Pharma Korea recently submitted a reimbursement application for its antibody-drug conjugate (ADC) Padcev (enfortumab vedotin). Accordingly, it will be interesting to see whether the company will be able
Company
Pharma-distributor 'margin war' heats up again
by
Son, Hyung Min
Jun 13, 2025 06:03am
The pharmaceutical industry and distribution industry are in conflict over profit margins. Janssen Korea reportedly notified its training companies of a 2%p reduction in margins and continuing negotiations with individual companies. Some domestic pharmaceutical companies are implementing margin reductions starting this year. Pharmaceutical co
Company
Distributors Association plans "strong response"
by
Son, Hyung Min
Jun 13, 2025 06:01am
The Korean pharmaceutical distribution industry is rallying around the Korea Pharmaceutical Distributors Association in response to Janssen Korea's reduction of&160;distribution margins. Park Ho-young, Chairman of the Korea Pharmaceutical Distributors Association, described Janssen Korea's margin reduction as an&160;arbitrary act&160;rath
Company
Trodelvy approved for reimbursement with the ICER value
by
Whang, byung-woo
Jun 12, 2025 06:06am
As Trodelvy (sacituzumab govitecan), the first antibody-drug conjugates (ADC) for treating Triple-Negative Breast Cancer (TNBC) available in South Korea, becomes reimbursed, a paradigm shift in the treatment is expected. Experts assess that the metastatic TNBC treatment, which has been challenging due to a high risk of metastasis and relapse
Company
Tevimbra seeks to add 6 indications in Korea
by
Eo, Yun-Ho
Jun 12, 2025 06:05am
The use of the immuno-oncology drug Tevimbra is set to be extended further in Korea. The Ministry of Food and Drug Safety is in the final stages of reviewing and approving the additional indications for BeOne Medicines Korea¡¯s Tevimbra (tiselizumab). The drug is expected to be approved for the extended indications within the month. Sp
Company
'Ocrevus' for multiple sclerosis available at hospitals
by
Eo, Yun-Ho
Jun 11, 2025 06:03am
The new drug 'Ocrevus' for treating multiple sclerosis is becoming available at general hospitals. According to sources, Roche Korea's Ocrevus (ocrelizumab), the treatment for relapsing multiple sclerosis (RMS), has passed drug committees of tertiary general hospitals, including Samsung Medical Center, Seoul National University, Asan Medic
Company
Janssen Korea to cut distribution margins¡¦ sparks pushback
by
Son, Hyung Min
Jun 11, 2025 06:03am
i1 Janssen Korea, which has announced a 2% reduction in distribution margins, is expected to engage in dialogue with individual pharmaceutical distribution companies rather than the Korea Pharmaceutical Distribution Association (KPDA) to resolve the current issue. The KPDA has sent two official letters to Janssen Korea, demanding negotiations
Company
Korean pharmas to make strong presence at BIO USA
by
Son, Hyung Min
Jun 11, 2025 06:02am
The domestic pharmaceutical and biotech industry will showcase its contract development and manufacturing (CDMO) and new drug candidate technologies at Bio USA, the world's largest biotech convention. Various Korean companies have also set out to participate in BIO USA 2025, which will be held in Boston, USA, for four days from the 16th of t
Company
EU revises pharma package law for the first time in 20 years
by
Kim, Jin-Gu
Jun 11, 2025 06:02am
The European Union (EU) is pushing for revisions to its ¡°Pharmaceutical Package¡± law on major drugs for the first time in 20 years. The core of the revision, which is now awaiting final approval by the European Parliament, can be summarized as expanding the exclusivity of innovative drugs and strengthening supply obligations within Euro
1
2
3
4
5
6
7
8
9
10
>